Trials / Completed
CompletedNCT00604006
SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Monash University · Academic / Other
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Accepted
Summary
Individuals who were a part of the investigators Screen-HF study (NCT00400257) whose BNP level are in the top quintile will be offered participation in this study. Participants will be randomised to receive either spironolactone or placebo for three years. Participants will then be monitored for indications of heart failure. It is anticipated that the medication will reduce the development of heart failure in this group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Spironolactone | 25 mg tablets (placed in capsules for blinding) once daily. |
| DRUG | Placebo | Placebo (lactose in capsules for blinding) once daily |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2014-08-01
- Completion
- 2015-01-01
- First posted
- 2008-01-29
- Last updated
- 2015-06-04
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT00604006. Inclusion in this directory is not an endorsement.